Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Alteral Therapeutics ApS
APS
Active
CVR 43730967
Bakkevej 41
Manufacture of pharmaceutical preparations · NACE 2120
Est. 2022
— employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
—
EBITDA margin
—
+93% vs 2023
Equity ratio
88.0%
Financial strength
Net profit 2024
DKK 20K
-93% vs 2023
EBITDA — year on year
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
—
—
EBITDA
DKK -6K
+93%
Net profit
DKK 20K
-93%
Total assets
DKK 403K
-3%
Equity
DKK 355K
+6%
Employees
—
—
Company information
Legal name
Alteral Therapeutics ApS
CVR number
43730967
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
22. december 2022
Share capital
DKK 40.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen i forening
Company purpose
Selskabets formål er at drive virksomhed med udvikling af lægemidler samt enhver virksomhed i hermed stående forbindelse.
Contact
Address
Bakkevej 41
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Manufacture of pharmaceutical preparations
Companies in Allerød
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
Income statement
DKK thousands
Item
2023
2024
Revenue
—
—
Staff expenses
-0
-0
EBITDA
-79
-6
Depreciation & amort.
-0
-0
EBIT
-79
-6
Net financials
373
26
Profit before tax
294
20
Tax
-0
-0
Net profit
294
20
Balance sheet
DKK thousands
Item
2023
2024
Total assets
416
403
Equity
334
355
Long-term debt
0
0
Short-term debt
82
48
Total debt
82
48
Financial ratios
5-year trend
EBITDA margin
-557400.0%
This company
15.8%
Market median
-3527948% vs market
2023
2024
Equity ratio
88.0%
This company
38.2%
Market median
+130% vs market
2023
2024
Return on equity
5.7%
This company
18.4%
Market median
-69% vs market
2023
2024
Net profit margin
2013700.0%
This company
8.1%
Market median
+24860394% vs market
2023
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2023
2024
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2022-12-22 – 2023-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
AT
Allan Traugott Wehnert
Management
Management
2023
—
—
RC
Rasmus Christian Drewes Jensen
Management
Management
2022
—
—
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Wehnert Holding ApS
Company
100.0%
100.0%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Wehnert Holding ApS
Alteral Therapeutics ApS
(this company)
NEUROINNOVATECH ApS
Novithera ApS
Board network connections
Board members of Alteral Therapeutics ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Allan Traugott Wehnert
Management
0 companies
Rasmus Christian Drewes Jensen
Management
0 companies